Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 13 Colorectal Neoplasms 6 Neoplasms 4 Thyroid Neoplasms 3 Prostatic Neoplasms 3 Ovarian Neoplasms 2 Colonic Neoplasms 2 Uterine Cervical Neoplasms 1 Unmet Fertility Information Needs 1 Thyroid Cancer, Papillary 1 Smoking Cessation 1 Patient Participation 1 Papillary Thyroid Microcarcinoma 1 Neuroma, Acoustic 1 Melanoma 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Kidney Neoplasms 1 Healthy Volunteers 1 Depression 1 Dementia 1 Colorectal Cancer Screening 1 Carcinoma, Renal Cell 1 Carcinoma, Medullary 1 Carcinoma, Intraductal, Noninfiltrating 1 COVID-19 1 Breast Carcinoma In Situ 1 Behavior 1 Advanced Cancer 1

Interventions

pembrolizumab 287 Nivolumab 258 Ipilimumab 236 Cyclophosphamide 135 aldesleukin 134 Interleukin-2 104 Temozolomide 75 Dacarbazine 74 trametinib 70 Vemurafenib 69 fludarabine 68 dabrafenib 65 fludarabine phosphate 62 sargramostim 44 binimetinib 44 Radiosurgery 44 Biopsy 43 Paclitaxel 42 Bevacizumab 42 incomplete Freund's adjuvant 39 encorafenib 37 Radiotherapy 36 Cisplatin 36 CTLA-4 Antigen 36 atezolizumab 35 Carboplatin 35 Magnetic Resonance Spectroscopy 33 cobimetinib 32 Specimen Handling 31 Introns 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma × Decision Support Techniques × Clear all

NCT04240717 2022-11-07

PEF-Immun

University Hospital Heidelberg

Phase NA Completed

Melanoma, Patient Participation

Data powered by HemOnc (CC BY 4.0) Colophon ⚡